Abstract 2022-RA-1148-ESGO Table 1

Responses to 1st line treatment

	Sig3+		Sig3-		p-value

	N	%	N	%
All patients	56		60
Primary therapy outcome					0.025
Complete response	38	69.1	28	47.5
Partial response	15	27.3	19	32.2
Stable disease			3	5.1
Progressive disease	2	3.6	9	15.3
No data	1		1
Platinum-free interval					<0.001
<6 months	11	20.4	30	50.8
6–12 months	9	16.7	17	28.8
>12 months	34	16.7	17	28.8